OneMedNet Appoints Former Allergan CEO Pyott to Board
Ticker: ONMDW · Form: 8-K · Filed: Aug 30, 2024 · CIK: 1849380
Sentiment: neutral
Topics: board-appointment, executive-changes, filing
Related Tickers: ONMD
TL;DR
OneMedNet adds former Allergan CEO David Pyott to its board. Big pharma experience incoming.
AI Summary
OneMedNet Corp. announced on August 26, 2024, the appointment of Dr. David E.I. Pyott as a new director. Dr. Pyott brings extensive experience from his tenure as CEO of Allergan, Inc. The company also reported on compensatory arrangements for its officers and filed financial statements and exhibits.
Why It Matters
The addition of a seasoned executive like Dr. Pyott, with a strong track record in the healthcare industry, could signal strategic growth or operational improvements for OneMedNet.
Risk Assessment
Risk Level: medium — The filing details board changes and compensatory arrangements, which can sometimes precede significant strategic shifts or financial reporting, introducing a moderate level of uncertainty.
Key Players & Entities
- OneMedNet Corp (company) — Registrant
- Dr. David E.I. Pyott (person) — Newly appointed director
- Allergan, Inc. (company) — Former employer of Dr. Pyott
- Data Knights Acquisition Corp. (company) — Former company name
FAQ
Who is Dr. David E.I. Pyott and what is his background?
Dr. David E.I. Pyott has been appointed as a director. He previously served as the CEO of Allergan, Inc.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is August 26, 2024.
What is the exact name of the registrant?
The exact name of the registrant is OneMedNet Corporation.
In which state was OneMedNet Corporation incorporated?
OneMedNet Corporation was incorporated in Delaware.
What was OneMedNet Corporation's former company name?
OneMedNet Corporation's former company name was Data Knights Acquisition Corp.
Filing Stats: 770 words · 3 min read · ~3 pages · Grade level 10.5 · Accepted 2024-08-30 17:08:25
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ONMD The Nasdaq
- $11.50 — of Common Stock at an exercise price of $11.50 per share ONMDW The Nasdaq Stock Ma
- $12,000 m — uant to which Mr. Golden will receive a $12,000 monthly salary and a grant of 100,000 res
Filing Documents
- form8-k.htm (8-K) — 46KB
- ex10-1.htm (EX-10.1) — 49KB
- 0001493152-24-034629.txt ( ) — 328KB
- onmd-20240826.xsd (EX-101.SCH) — 4KB
- onmd-20240826_def.xml (EX-101.DEF) — 29KB
- onmd-20240826_lab.xml (EX-101.LAB) — 36KB
- onmd-20240826_pre.xml (EX-101.PRE) — 27KB
- form8-k_htm.xml (XML) — 6KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Consulting Agreement, dated August 30, 2024, between OneMedNet Corporation and Robert Golden. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 30, 2024 ONEMEDNET CORPORATION By: /s/ Aaron Green Aaron Green Chief Executive Officer